Skip to main content
. 2018 Mar 23;2018(3):CD010840. doi: 10.1002/14651858.CD010840.pub2

NCT02210728.

Trial name or title Efficacy of cognitive behavioral therapy in treatment of adults with attention deficit hyperactivity disorder
Methods Allocation: randomised
Intervention Model: parallel Assignment
Participants This study is ongoing, but not recruiting participants.
Inclusion criteria

  1. DSM‐IV‐TR criteria for adult ADHD of any of three subtypes via Conners' Adult ADHD Diagnostic Interview for the DSM‐IV (CAAR‐D) and clinician's assessment

  2. Barkley Childhood and Current Symptom of ADHD (1998) completed by self and informants (parents or siblings). Required cutoff's on these scales are scores 1.5 SDs above relevant gender and age norms

  3. Conners' Adult ADHD Rating Scale (1999). Required cutoff's on these scales are scores 1.5 SDs above relevant gender and age norms

  4. Between 18 and 60 years old

  5. Be able to give informed consent and comply with study procedures

  6. IQ of 80 or above on Wechsler Adult Intelligence Scale, 3rd edition (WAIS‐III) subtests of 3 verbal and 3 nonverbal subtests

  7. Adequate command of English to be able to participate in CBT group.


Exclusion criteria

  1. Psychotic symptoms, past or current

  2. Current psychiatric comorbidity, e.g. bipolar disorder, depression, suicidal ideation, current substance use disorder (must be free of substance abuse for 6 months)

  3. Medical condition that precludes use of the stimulant medication, e.g. hypertension, cardiac disease, Tourette's Syndrome, etc.

  4. Organic mental disorders or other significant neurological disorders, e.g. epilepsy, head injury, chorea, multiple sclerosis, deafness, blindness
Interventions Stimulant medication only versus CBT only vs combined CBT and stimulant medication group
Outcomes Primary outcome measures

  1. Self‐reported ADHD symptoms (measured via Barkley's Current ADHD Symptoms Scale)

  2. Self‐reported ADHD symptoms (measured via Barkley's Current ADHD Symptoms Scale)

  3. Self‐reported ADHD symptoms (measured via Barkley's Current ADHD Symptoms Scale)

  4. Self‐reported ADHD symptoms (measured via Barkley's Current ADHD Symptoms Scale)

  5. Self‐reported ADHD symptoms (measured via Barkley's Current ADHD Symptoms Scale)


Secondary outcome measures

  1. Global psychological distress (measured via the Symptom Checklist 90)

  2. Depression symptoms (via the Beck Depression Inventory)

  3. Anxiety symptoms (measured via the Beck Anxiety Inventory)

  4. Global functional impairment (measured via the Sheehan Disability Scale)

  5. Dyadic adjustment (for those married or cohabiting, measured via the Dyadic Adjustment Scale)

  6. Organisational skills (measured via the Organization and Activation for Work Scale)

  7. Self‐esteem (measured via the Index of Self‐Esteem)

  8. Anger expression (measured via the State Trait Anger Expression Inventory ‐ II)

  9. Observer‐Rated ADHD symptoms (measured via the Barkley's Current ADHD Symptoms Scale ‐‐ observer version)
Starting date Start date: April 2006
End date: October 2017
Recruitment status: active, not recruiting
Contact information Dr Lily Hechtman. McGill University Health Center
Notes Funding source: McGill University Health Center
Declarations of interest: not reported